Evidence map›Paper›PMID 34689049›Full record

ArticleJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association2022

Utilization and Outcomes of Acute Revascularization Treatments in Ischemic Stroke Patients with SARS-CoV-2 Infection.

Adnan I Qureshi, William I Baskett, Wei Huang, Muhammad F Ishfaq, S Hasan Naqvi, Brandi R French, Farhan Siddiq, Camilo R Gomez, Chi-Ren Shyu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Dual antiplatelet use in the management of COVID-19 associated acute ischemic stroke reocclusion.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2023
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adnan I QureshiZeenat Qureshi Stroke Insititute and Department of Nuerology, University of Missouri, One Hospital Dr., CE507, Columbia MO 65212, USA.
William I BaskettInstitute for Data Science and Informatics, University of Missouri, Columbia, MO, USA.
Wei HuangZeenat Qureshi Stroke Insititute and Department of Nuerology, University of Missouri, One Hospital Dr., CE507, Columbia MO 65212, USA. Electronic address: xiaohuanggo123@gmail.com.
Muhammad F IshfaqDepartment of Neurology, University of Missouri, Columbia, MO, USA.
S Hasan NaqviDepartment of Medicine, University of Missouri, Columbia, MO, USA.
Brandi R FrenchDepartment of Neurology, University of Missouri, Columbia, MO, USA.
Farhan SiddiqDivision of Neurosurgery, University of Missouri, Columbia, MO, USA.
Camilo R GomezDepartment of Neurology, University of Missouri, Columbia, MO, USA.
Chi-Ren ShyuInstitute for Data Science and Informatics, University of Missouri, Columbia, MO, USA; Department of Medicine, University of Missouri, Columbia, MO, USA; Department of Electrical Engineering and Computer Science, University of Missouri, Columbia, MO, USA.

Funding

Massive and Complex Data Analytics Pre-Doctoral Training in One HealthT32LM012410 · NLM · UNIVERSITY OF MISSOURI-COLUMBIA · PI SHYU, CHI-REN · 2016 to 2020
$1.2M
NLM NIH HHS T32 LM012410
6 · The paper itself

Abstract

objectivesAcute ischemic stroke patients with severe acute respiratory syndrome coronavirus maybe candidates for acute revascularization treatments (intravenous thrombolysis and/or mechanical thrombectomy). MATERIALS AND

methodsWe analyzed the data from 62 healthcare facilities to determine the odds of receiving acute revascularization treatments in severe acute respiratory syndrome coronavirus infected patients and determined the odds of composite of death and non-routine discharge with severe acute respiratory syndrome coronavirus infected and non-infected patients undergoing acute revascularization treatments after adjusting for potential confounders.

resultsAcute ischemic stroke patients with severe acute respiratory syndrome coronavirus infection were significantly less likely to receive acute revascularization treatments (odds ratio 0.6, 95% confidence interval 0.5-0.8, p = 0.0001). Among ischemic stroke patients who received acute revascularization treatments, severe acute respiratory syndrome coronavirus infection was associated with increased odds of death or non-routine discharge (odds ratio 3.0, 95% confidence interval 1.8-5.1). The higher odds death or non-routine discharge (odds ratio 2.1, 95% confidence interval 1.9-2.3) with severe acute respiratory syndrome coronavirus infection were observed in all ischemic stroke patients without any modifying effect of acute revascularization treatments (interaction term for death (p = 0.9) or death or non-routine discharge (p = 0.2).

conclusionsPatients with acute ischemic stroke with severe acute respiratory syndrome coronavirus infection were significantly less likely to receive acute revascularization treatments. Severe acute respiratory syndrome coronavirus infection was associated with a significantly higher rate of death or non-routine discharge among acute ischemic stroke patients receiving revascularization treatments.

Indexed as

ThrombectomyThrombolytic TherapyAdultAgedAged, 80 and overBrain IschemiaCOVID-19FemaleHumansIschemic StrokeMaleMiddle AgedSARS-CoV-2StrokeAcute ischemic strokeMechanical thrombectomyRevascularizationSARS-CoV-2Thrombolysis

Identifiers

PMID34689049
PMCPMC8498748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.